Latest news with #CNW
Cision Canada
3 hours ago
- Business
- Cision Canada
China Mobile and ZTE win the Asia Mobile Award 2025 with AI-driven 5G cloudified core network
China Mobile and ZTE have developed the innovative AI-driven green and energy-saving 5G cloudified core network project to reduce the energy consumption and improve the network performance and operation efficiency The AI-driven green and energy-saving 5G cloudified core network innovative and replicable solution helps operators reduce OPEX and CAPEX while achieving significant energy saving effect SHANGHAI, June 20, 2025 /CNW/ -- ZTE Corporation ( / a global leading provider of integrated information and communication technology solutions, in partnership with China Mobile, has earned "Best Mobile Innovation for Climate Action in Asia" award for their AI-driven green and energy-saving 5G cloudified core network innovation project at the Asia Mobile Awards(AMOs) during MWC Shanghai 2025. Energy conservation, emission reduction and green transformation in the communications industry are key issues in the global shift towards green and sustainable development. The innovative AI-driven green and energy-saving 5G cloudified core network project aims to significantly reduce the energy consumption of the 5G core network while enhancing network performance and operation efficiency through the innovative cloud-native architecture and intelligent energy-saving technology. Leveraging ZTE's leading Intelligent 5G core network solutions and China Mobile's extensive experience in green communications, this project successfully achieves energy efficiency optimization and carbon emission reduction of 5G core network, providing operators with efficient and environmentally-friendly 5G core network deployment solutions. The AI-driven green and energy-saving 5G cloudified core network innovation project not only helps operators reduce OPEX and CAPEX, but also provides replicable solutions for the sustainable development of global 5G core networks. To date, this project has been deployed across multiple provinces of China, achieving significant energy savings. Moving forward, ZTE will further its collaboration with China Mobile to promote the application of green and energy-saving technologies in a wider range of network systems. Both parties will work together with global partners to advance the green and intelligent development of 5G networks, with great commitment to the sustainable development of the global communications industry. ABOUT ZTE: ZTE connects the world with continuous innovation for a better future. The company provides innovative technologies and integrated solutions, and its portfolio spans communication networks, computing infrastructure, industry digital solutions, and personal and home smart terminals. Serving over a quarter of the world's population, ZTE is dedicated to leading globally in connectivity and intelligent computing, enabling communication and trust everywhere. ZTE is listed on both the Hong Kong and Shenzhen Stock Exchanges.
Cision Canada
3 hours ago
- Automotive
- Cision Canada
Safety Under Pressure: Chery Battery Faces Indonesian Ocean for 53+Hours
JAKARTA, Indonesia, June 20, 2025 /CNW/ -- On June 17, Chery commenced the second stage of its Global Safety Challenge in Jakarta, Indonesia, focusing on the "extreme humidity" scenario within its six-dimensional safety evaluation system (heat, cold, dryness, humidity, high-speed, and rough terrain). This rigorous test validated the moisture and corrosion resistance of the "Guardian Battery" in Chery Super Hybrid (CSH). Mr. Heri Prabowo, Head of the Sub-Directorate of Motor Vehicle Type Testing, Ministry of Transportation, and Mr. Christian Andersen, Notary, along with representatives from 80 leading media outlets and industry KOLs, attended the event to witness the battery's performance after 53 hours and 51 minutes of continuous saltwater soaking—demonstrating zero leakage, zero short circuit, and no signs of thermal runaway. The battery maintained structural integrity and passed all technical validations for electrical insulation. Once installed in the vehicle, it started successfully on the first attempt and delivered stable power throughout the road test, completing the rigorous challenge with zero anomalies. CSH's "Guardian Battery" features IP68-rated waterproof and dustproof certification, an ultra-fast 2ms power cut-off response, an ultra-wide operating temperature range from -35°C to 60°C, and a 24/7 real-time health monitoring system—delivering comprehensive battery safety backed by advanced intelligent technologies. On the passive protection front, TIGGO8 CSH is equipped with a high-strength steel underbody shield with a tensile strength of 780 MPa, significantly enhancing the vehicle's overall safety performance. At the event, TIGGO8 CSH's spacious "5+2" seating layout and V2L ecosystem drew significant attention from guests. With the third-row seats folding flat at the touch of a button, the class-leading 1,930L trunk, paired with 36 storage compartments and a powerful 3.3 kW V2L system, TIGGO8 CSH provides a comfortable and enjoyable travel experience for the whole family on every journey. Committed to safety excellence, Chery continuously elevates technological innovation with user-centric engineering, benchmarking against industry leaders like Volvo through rigorous global safety challenges. As the second stage in Chery's global safety challenge, the Indonesian battery safety test in extreme humidity further validated the brand's safety technology. Looking ahead, Chery will conduct a rigorous underbody scraping test in the Mexican market to further evaluate the safety performance of CSH—highlighting Chery's commitment to delivering safer and more reliable mobility solutions to global customers.
Cision Canada
3 hours ago
- Business
- Cision Canada
TrinaTracker Ranks Among Top 3 in Key European Solar Tracker Markets According to Wood Mackenzie
CHANGZHOU, China, June 20, 2025 /CNW/ -- The renowned research institution Wood Mackenzie has released its Global solar PV tracker market share report 2025, ranking TrinaTracker sixth globally and fourth in major regions including Europe, the Middle East, Latin America, and Asia Pacific. These results align with the company's strategy of delivering high-quality tracker solutions while focusing on premium markets. Top 4 in Europe, TOP 3 in Spain and Italy The report highlights TrinaTracker's position as the fourth-leading provider in the European market, with particularly strong performance in Spain and Italy, where TrinaTracker ranks third. Europe emerged as TrinaTracker's second-largest market in 2024, accounting for 29.2% of its total shipments. Beyond shipment volume, Europe serves as a key hub for TrinaTracker's flagship projects showcasing its latest technological innovation. For instance, at the Campina project in Spain, TrinaTracker partnered with third-party UL to conduct field tests on its self-developed SuperTrack smart tracking algorithm. The results demonstrated a 2.21% boost in solar plant performance on average, with an impressive 9.15% improvement on typical cloudy days. Rapid Expansion in the Middle East The Middle East saw solar tracker shipments surge to 15.449 GW in 2024, more than doubling from the previous year. Saudi Arabia dominated the region as the largest market, contributing over 12 GW. TrinaTracker ranks fourth in the region, driven by major projects in the UAE and Saudi Arabia. In early 2025, TrinaTracker announced the opening of a 3 GW factory in Saudi Arabia and the delivery of its Vanguard 1P trackers to the PIF4 Al Khushaybi PV Project, further accelerating its growth in the region. Till end of Q1 2025, TrinaTracker has cumulatively delivered around 30GW of its smart mounting systems to more than 60 countries. Through years of operation, TrinaTracker has garnered widespread praise for its products and services. This year, the company aims to strengthen its global presence by offering localized, low-LCOE solar tracker solutions, anticipating steady business growth in the years ahead.
Cision Canada
5 hours ago
- Business
- Cision Canada
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") announces that it has amended the terms of its brokered private placement LIFE financing (the " Offering") previously announced on May 30, 2025, and filed an amended offering document (the " Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units (" Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the " Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the " Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a " Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a " Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (" NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption (" LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARD Signed " James Passin" James Passin, Chief Executive Officer Phone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively " forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
Cision Canada
6 hours ago
- Health
- Cision Canada
New Global Aesthetics Report: A Shift Towards Facial Surgery Globally as Eyelid Ranks Top Procedure Français
Aesthetic Procedures Close to 38 Million in 2024. MOUNT ROYAL, N.J., June 20, 2025 /CNW/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures at the ISAPS Olympiad World Congress in Singapore, showing more than 17.4 million procedures performed by plastic surgeons and 20.5 non-surgical procedures. Over the last four years, the overall increase is 42.5%. Aesthetic Procedures Eyelid surgery, for the first time, was the most common surgical procedure in 2024, replacing liposuction, with 2.1 million, followed by liposuction, breast augmentation, scar revision, and rhinoplasty. The most popular non-surgical procedures were botulinum toxin, hyaluronic acid (filler), hair removal, non-surgical skin tightening, and chemical peels. Most face and head procedures showed growth from the previous year, with more than 7.4 million procedures and a 4.3% increase. Top procedures were eyelid surgery with more than 2.1 million and a 13.4% increase, rhinoplasty with 1 million procedures and a 10% decrease, and fat grafting – face 0.9 million and a 19.2% increase. There were 3.9 million breast procedures (-14.1%) and 6 million body and extremities procedures (-14.8%). Liposuction was still the most common surgical procedure for women, followed by eyelid surgery and breast augmentation. Eyelid surgery was again the most popular surgical procedure among men, followed by gynecomastia and scar revision. Most breast augmentations (54% of the total), rhinoplasties (60.1%), and external genital surgery (48.4%) took place on 18–34-year-olds, whereas botulinum toxin injectables were most popular among those aged 35–50 (47.0% of the total). Liposuction and non-surgical fat reduction were distributed quite evenly among both age groups. Botulinum toxin remained the most common non-surgical procedure for both men and women and among all age groups, with 7.8 million procedures performed by plastic surgeons worldwide. In second place, hyaluronic acid procedures increased by 5.2% to 7.8 million. Commenting on the global results, Dr. Amin Kalaaji, Chair of the ISAPS Global Survey Committee and plastic surgeon in Norway, said, "Our report now includes data on 'Mommy Makeover' and other combined procedures, scar revision, hand rejuvenation with fat grafting, buccal fat removal, inverted nipple correction, dimple creation, and other outer genital surgery." Once again, the US performed the most procedures with over 6.1 million, followed by Brazil with 3.1 million (which is first in surgical procedures), and Japan. For media inquiries, please contact [email protected].
